دورية أكاديمية
Epstein-Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada.
| العنوان: | Epstein-Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada. |
|---|---|
| المؤلفون: | Ratiu C; Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada., Dufresne SF; Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.; Division of Infectious Diseases and Clinical Microbiology, Department of Medicine, Maisonneuve-Rosemont Hospital, Montréal, QC H1T 2M4, Canada.; Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada., Thiant S; Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada.; Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, 5415 de l'Assomption, Montréal, QC H1T 2M4, Canada., Roy J; Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.; Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada.; Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, 5415 de l'Assomption, Montréal, QC H1T 2M4, Canada. |
| المصدر: | Current oncology (Toronto, Ont.) [Curr Oncol] 2024 May 14; Vol. 31 (5), pp. 2780-2795. Date of Electronic Publication: 2024 May 14. |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : Basel, Switzerland : MDPI Original Publication: Toronto : Multimed, c1994- |
| مواضيع طبية MeSH: | Hematopoietic Stem Cell Transplantation*/adverse effects , Hematopoietic Stem Cell Transplantation*/methods , Epstein-Barr Virus Infections* , Herpesvirus 4, Human*, Humans ; Canada ; Rituximab/therapeutic use ; Transplantation, Homologous/methods ; Lymphoproliferative Disorders/etiology |
| مستخلص: | Epstein-Barr virus-related post-transplantation lymphoproliferative disorder (EBV-PTLD) is a serious complication following hematopoietic stem cell transplantation (HSCT). A pre-emptive strategy using rituximab, which aims to manage patients early at the time of EBV reactivation to avoid PTLD, has been recommended by the most recent ECIL-6 guidelines in 2016. However, there is still a great heterogeneity of viral-load monitoring protocols, targeted patient populations, and pre-emptive treatment characteristics between centers, making precise EBV monitoring recommendations difficult. We conducted a literature review from the most recent publications between 1 January 2015 and 1 August 2023, to summarize the emerging data on EBV-PTLD prevention strategies in HSCT recipients, including the EBV-DNA threshold and use of rituximab. We also present the results of a survey of current practices carried out in 12 of the main HSCT centers across Canada. We confirm that pre-emptive rituximab remains an efficient strategy for EBV-PTLD prevention. However, there is an urgent need to perform prospective, randomized, multicentric trials with larger numbers of patients reflecting current practices to determine the best clinical conduct with regards to rituximab dosing, timing of treatment, and criteria to initiate treatments. Longer follow-ups will also be necessary to assess patients' long-term outcomes. |
| References: | Pediatr Transplant. 2021 Nov;25(7):e14052. (PMID: 34076939) Transplant Cell Ther. 2021 Aug;27(8):682.e1-682.e12. (PMID: 33962069) Leuk Lymphoma. 2020 Dec;61(13):3198-3208. (PMID: 32715815) Biol Blood Marrow Transplant. 2018 Aug;24(8):1699-1706. (PMID: 29545186) Pediatr Int. 2017 Sep;59(9):973-978. (PMID: 28581032) Cytotherapy. 2018 May;20(5):706-714. (PMID: 29580864) J Clin Virol. 2010 Jun;48(2):82-90. (PMID: 20395167) Mol Med Rep. 2019 Mar;19(3):1435-1442. (PMID: 30592278) Blood. 2016 Apr 21;127(16):2007-17. (PMID: 26744460) Transpl Infect Dis. 2016 Feb;18(1):44-54. (PMID: 26574232) Int J Hematol. 2022 Apr;115(4):525-533. (PMID: 35226308) Ann Hematol. 2019 Apr;98(4):987-996. (PMID: 30715567) Leukemia. 2022 Jul;36(7):1720-1748. (PMID: 35732829) Curr Res Transl Med. 2019 Nov;67(4):145-148. (PMID: 30871955) Haematologica. 2016 Jul;101(7):803-11. (PMID: 27365460) Leuk Lymphoma. 2018 May;59(5):1172-1179. (PMID: 28831836) Bone Marrow Transplant. 2020 Sep;55(9):1754-1762. (PMID: 32066862) Mol Med Rep. 2018 Nov;18(5):4650-4656. (PMID: 30221663) Oncotarget. 2018 Jan 27;9(14):11451-11464. (PMID: 29545911) Leuk Lymphoma. 2019 Jul;60(7):1693-1696. (PMID: 30741059) Blood. 2013 Aug 22;122(8):1510-7. (PMID: 23861248) Vox Sang. 2017 Jul;112(5):459-468. (PMID: 28466551) Ann Hematol. 2019 Sep;98(9):2163-2177. (PMID: 31243569) Blood Adv. 2022 Sep 13;6(17):4949-4966. (PMID: 35819448) Biol Blood Marrow Transplant. 2018 Nov;24(11):2259-2264. (PMID: 30009980) Biol Blood Marrow Transplant. 2019 Sep;25(9):1837-1843. (PMID: 31128324) Transplant Cell Ther. 2023 Feb;29(2):132.e1-132.e5. (PMID: 36334653) J Cancer Res Clin Oncol. 2018 Aug;144(8):1569-1580. (PMID: 29804164) BMC Med. 2019 Aug 12;17(1):156. (PMID: 31401973) Front Cell Infect Microbiol. 2022 Sep 16;12:980113. (PMID: 36189344) Ann Hematol. 2021 Jul;100(7):1879-1889. (PMID: 33885923) Bone Marrow Transplant. 2020 Jan;55(1):25-39. (PMID: 31089285) Indian J Hematol Blood Transfus. 2017 Dec;33(4):525-533. (PMID: 29075063) Bone Marrow Transplant. 2015 Apr;50(4):579-84. (PMID: 25581404) J Clin Microbiol. 2016 Jul;54(7):1746-1750. (PMID: 27076661) Biologicals. 2016 Sep;44(5):423-33. (PMID: 27461128) Oncologist. 2021 Nov;26(11):e2034-e2041. (PMID: 34506688) Cancers (Basel). 2021 Sep 12;13(18):. (PMID: 34572803) Bone Marrow Transplant. 2016 Jun;51(6):825-32. (PMID: 26901708) Transplant Cell Ther. 2022 Mar;28(3):173.e1-173.e6. (PMID: 34954150) Diagn Microbiol Infect Dis. 2016 Aug;85(4):428-32. (PMID: 27312691) Transpl Int. 2017 Jan;30(1):57-67. (PMID: 27717030) Clin Immunol. 2019 Aug;205:49-56. (PMID: 31112757) Biol Blood Marrow Transplant. 2019 Jul;25(7):1441-1449. (PMID: 30794929) Hematol Oncol Stem Cell Ther. 2019 Sep;12(3):171-173. (PMID: 30543769) Transpl Infect Dis. 2008 Oct;10(5):308-15. (PMID: 18466193) Haematologica. 2022 Apr 01;107(4):857-867. (PMID: 33832208) Transplant Cell Ther. 2022 Jan;28(1):53.e1-53.e10. (PMID: 34607072) Pediatr Transplant. 2019 Dec;23(8):e13574. (PMID: 31496046) Front Oncol. 2023 Feb 16;13:1071268. (PMID: 36874098) Bone Marrow Transplant. 2020 Mar;55(3):586-594. (PMID: 31562397) Blood. 2009 Jan 15;113(3):604-11. (PMID: 18845794) Transpl Infect Dis. 2021 Oct;23(5):e13719. (PMID: 34453768) Transpl Infect Dis. 2018 Feb;20(1):. (PMID: 29178248) Front Immunol. 2022 Jul 12;13:903063. (PMID: 35903096) Transplant Cell Ther. 2023 Jan;29(1):43.e1-43.e8. (PMID: 36273783) Ann Hematol. 2021 Jul;100(7):1913-1915. (PMID: 34081155) Rev Med Virol. 2020 Jul;30(4):e2108. (PMID: 32301566) Exp Hematol. 2011 Sep;39(9):892-6. (PMID: 21703987) Int J Hematol. 2016 Nov;104(5):628-635. (PMID: 27431489) Bone Marrow Transplant. 2021 Jul;56(7):1651-1664. (PMID: 33623153) Front Immunol. 2020 Sep 16;11:567020. (PMID: 33042147) Diagnostics (Basel). 2023 Jan 28;13(3):. (PMID: 36766581) Transpl Infect Dis. 2016 Dec;18(6):889-895. (PMID: 27696681) Leuk Lymphoma. 2019 Jan;60(1):110-117. (PMID: 29979906) J Clin Virol. 2017 Dec;97:26-32. (PMID: 29096390) Transplantation. 2010 Jun 27;89(12):1533-40. (PMID: 20463647) Ann Hematol. 2021 Apr;100(4):865-878. (PMID: 33547921) Biol Blood Marrow Transplant. 2017 Mar;23(3):483-490. (PMID: 28039080) J Clin Exp Hematop. 2021 Mar 18;61(1):1-9. (PMID: 33551435) Pediatr Transplant. 2019 Feb;23(1):e13319. (PMID: 30417487) Transpl Infect Dis. 2019 Dec;21(6):e13182. (PMID: 31556214) |
| فهرسة مساهمة: | Keywords: Epstein–Barr virus; allogeneic stem cell transplant; post-transplant lymphoproliferative disorder; pre-emptive treatment; risk factors; rituximab; viral reactivation |
| المشرفين على المادة: | 4F4X42SYQ6 (Rituximab) |
| تواريخ الأحداث: | Date Created: 20240524 Date Completed: 20240524 Latest Revision: 20240610 |
| رمز التحديث: | 20240611 |
| مُعرف محوري في PubMed: | PMC11119229 |
| DOI: | 10.3390/curroncol31050211 |
| PMID: | 38785492 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1718-7729 |
|---|---|
| DOI: | 10.3390/curroncol31050211 |